NCT03045341View on ClinicalTrials.gov

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

February 27, 2017

Primary Completion Date

July 23, 2021

Study Completion Date

December 16, 2022

Conditions
Binge-eating DisorderObesity
Interventions
DRUG

NB medication (Naltrexone Bupropion combination)

NB medication

BEHAVIORAL

Behavioral Weight Loss (BWL) counseling

BWL counseling

OTHER

Placebo

Placebo

Trial Locations (1)

06520

Yale School of Medicine, New Haven

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Yale University

OTHER

NCT03045341 - Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment | Biotech Hunter | Biotech Hunter